Develops tumor‑targeting biologics that enhance immune surveillance to accelerate delivery of high‑quality therapeutics to patients, advancing antibody candidates from discovery to IND‑enabling studies. Uses multiple advanced antibody discovery platforms, transgenic‑mouse‑based libraries, and collaborative venture‑studio partnerships to speed candidate selection.